Laboratory of Health Science, Postgraduate Program in Health Sciences, Universidade Estadual de Montes Claros, Montes Claros, Minas Gerais, Brazil; Educational Institute Santo Agostinho, Minas Gerais, Brazil.
Laboratory of Health Science, Postgraduate Program in Health Sciences, Universidade Estadual de Montes Claros, Montes Claros, Minas Gerais, Brazil.
Biomed Pharmacother. 2019 Apr;112:108634. doi: 10.1016/j.biopha.2019.108634. Epub 2019 Feb 21.
The present study aimed to evaluate the effects of resveratrol on FNDC5 and thermogenesis markers expression in the adipose tissue of mice and humans. Thirty-two male mice were randomly divided into four groups (n = 8) and fed with: Standard Diet; Standard Diet + Resveratrol (400 mg/kg); High-fat Diet; High-fat Diet + Resveratrol for eight weeks. Twenty male and female volunteers, aged 30-55 years, BMI ≥ 30 kg/m² were divided into two groups and treated for four weeks with 500 mg trans-resveratrol or placebo, adipose tissue biopsies were taken. Analysis of body weight, food intake, glycemic and lipid profiles, mRNA expression from tissues and primary culture of adipocytes were performed. The main results show that resveratrol improves the glycaemic and lipid profiles along with an increase in the levels of UCP1, PRDM16, PGC1α, and SIRT1. The increase in FNDC5 expression was observed in the mouse and human subcutaneous adipose tissue. The SIRT1 antagonist in adipocyte primary culture resulted in decreased FNDC5 expression. Our data suggest that improved metabolism produced by oral administration of resveratrol is, at least in part, associated with increased thermogenesis followed by high expression of UCP1, PRDM16, PGC1α and that increased FNDC5 expression in the subcutaneous adipose tissue from mice and human might be modulated by SIRT1.
本研究旨在评估白藜芦醇对脂肪组织中 FNDC5 和产热标志物表达的影响,分别在小鼠和人体上进行实验。32 只雄性小鼠被随机分为四组(每组 8 只),分别喂食标准饮食、标准饮食+白藜芦醇(400mg/kg)、高脂饮食和高脂饮食+白藜芦醇 8 周。20 名年龄在 30-55 岁之间、BMI≥30kg/m²的男性和女性志愿者被分为两组,分别服用四周的 500mg 反式白藜芦醇或安慰剂,取脂肪组织活检。分析体重、食物摄入量、血糖和血脂谱、组织和原代脂肪细胞的 mRNA 表达。主要结果表明,白藜芦醇改善了血糖和血脂谱,同时增加了 UCP1、PRDM16、PGC1α 和 SIRT1 的水平。在小鼠和人体的皮下脂肪组织中观察到 FNDC5 表达增加。在脂肪细胞原代培养中使用 SIRT1 拮抗剂可导致 FNDC5 表达减少。我们的数据表明,口服白藜芦醇改善代谢至少部分与增加产热有关,随后 UCP1、PRDM16、PGC1α 的表达增加,并且来自小鼠和人体的皮下脂肪组织中 FNDC5 的表达增加可能受 SIRT1 调节。